Showing results (91-100 of 144) with videos related to
Sort By:
Pageof 15
International Journal of Radiation Oncology, Biology, Physics|October 14, 2015
Definitive Management of Oligometastatic Melanoma in a Murine Model Using Combined Ablative Radiation Therapy and Viral ImmunotherapyMiran Blanchard, Kevin G Shim, Michael P Grams, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|May 5, 2019
Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase InhibitionVictoria A Jennings, Gina B Scott, Ailsa M S Rose, et al.Oncoimmunology|June 7, 2018
Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trialPoulam M Patel, Christian H Ottensmeier, Clive Mulatero, et al.Molecular Oncology|January 27, 2016
Integrated analysis of the prostate cancer small-nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progressionFrancesco Crea, Luca Quagliata, Agnieszka Michael, et al.Science Translational Medicine|April 13, 2022
Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in miceLaura Evgin, Tim Kottke, Jason Tonne, et al.Nature Communications|February 9, 2020
APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapyChristopher B Driscoll, Matthew R Schuelke, Timothy Kottke, et al.Cancer Immunology Research|April 4, 2019
Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line TreatmentLaura Evgin, Amanda L Huff, Timothy Kottke, et al.Journal for Immunotherapy of Cancer|March 26, 2022
CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanomaGalabina Bozhanova, Jehanne Hassan, Lizzie Appleton, et al.Nature Communications|March 27, 2021
Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapyTimothy Kottke, Jason Tonne, Laura Evgin, et al.Scientific Reports|June 25, 2013
Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk menEmma Killick, Richard Morgan, Francesca Launchbury, et al.Pageof 15